← Back to headlines
Ultragenyx Stock Drops Following Failed Phase 3 Clinical Trial Results
Shares of biotech firm Ultragenyx fell significantly after its Phase 3 Aspire study failed to meet its primary efficacy endpoint.
3 Sept, 11:00 — 3 Sept, 11:00
Sources
Showing 1 of 1 sources
